What is Roth Capital’s Forecast for RVPH FY2025 Earnings?

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – Investment analysts at Roth Capital lifted their FY2025 EPS estimates for Reviva Pharmaceuticals in a research note issued on Sunday, November 16th. Roth Capital analyst B. Pachaiyappan now expects that the company will post earnings of ($0.35) per share for the year, up from their previous forecast of ($0.45). Roth Capital currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($0.97) per share. Roth Capital also issued estimates for Reviva Pharmaceuticals’ Q4 2025 earnings at ($0.05) EPS, Q1 2026 earnings at ($0.05) EPS, Q2 2026 earnings at ($0.04) EPS, Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at ($0.04) EPS and FY2026 earnings at ($0.17) EPS.

Several other brokerages have also commented on RVPH. Chardan Capital began coverage on Reviva Pharmaceuticals in a report on Monday, September 29th. They issued a “buy” rating and a $2.00 price objective for the company. Maxim Group cut their price target on Reviva Pharmaceuticals from $5.00 to $2.00 and set a “buy” rating for the company in a research note on Friday, August 15th. HC Wainwright reduced their price target on shares of Reviva Pharmaceuticals from $11.00 to $4.00 and set a “buy” rating for the company in a research report on Monday, October 27th. Citigroup reiterated a “buy” rating on shares of Reviva Pharmaceuticals in a research note on Friday, August 15th. Finally, D. Boral Capital restated a “buy” rating and set a $2.00 target price on shares of Reviva Pharmaceuticals in a research report on Tuesday, October 28th. Eight investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $3.86.

Reviva Pharmaceuticals Trading Up 10.1%

Shares of RVPH opened at $0.53 on Wednesday. The firm has a fifty day simple moving average of $0.51 and a two-hundred day simple moving average of $0.57. The firm has a market cap of $36.87 million, a PE ratio of -1.16 and a beta of -0.04. Reviva Pharmaceuticals has a 1-year low of $0.25 and a 1-year high of $4.28.

Reviva Pharmaceuticals (NASDAQ:RVPH) last issued its earnings results on Thursday, November 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.05.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. NewEdge Advisors LLC purchased a new stake in Reviva Pharmaceuticals in the 1st quarter worth approximately $58,000. XTX Topco Ltd purchased a new position in Reviva Pharmaceuticals during the second quarter valued at approximately $31,000. Lido Advisors LLC purchased a new position in Reviva Pharmaceuticals during the third quarter valued at approximately $37,000. Private Advisor Group LLC bought a new position in shares of Reviva Pharmaceuticals in the first quarter worth approximately $191,000. Finally, Geode Capital Management LLC increased its stake in shares of Reviva Pharmaceuticals by 6.9% in the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after purchasing an additional 29,063 shares in the last quarter. 63.18% of the stock is owned by hedge funds and other institutional investors.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.